(2) Nebulisers should be used only in conjunction with a peak flow meter (except in very young children).
(2) Nebulisers should be used only in conjunction with a peak flow meter (except in very young children).
(3) Nebulisers should not be used regularly at first but should be reserved for acute exacerbations when peak flow measurements are below a certain predetermined value.
(4) Ideally, a bank of nebulisers should be available for loan so that patients can have a trial period before purchase. (5) Patients should receive: (a) full instructions on how to use and clean their nebuliser from a suitably trained person such as a respiratory function technician or a physiotherapist, and (b) clear instructions on the use of the nebuliser in an acute attack. Maximum single dose should be 5 mg salbutamol or 10 mg terbutaline, and maximum daily dose 15 mg salbutamol or 30 mg terbutaline. Patients should seek help immediately if the stipulated peak flow response is not achieved or the bronchodilator response is not maintained and start a crash course of oral steroids from a "home depot." (6) Nebulisers are to be used as an adjunct, not an alternative, to normal treatment for asthma.
(7) Patients using nebulisers should remain under regular surveillance by the district nebuliser service, and arrangements should be made to carry out maintenance on the nebulisers yearly.
The limitations on the maximum dose in the above recommendations will, we hope, remind patients that if their asthma does not respond, alternative treatment such as a crash course of steroids might be more appropriate than increasing the dose of nebulised bronchodilator. Of course, the recommendations do not apply to the dose that can be given by doctors personally, either in the home or in hospital, to treat acute exacerbations. Doses administered to patients with severe chronic airflow obstruction may also be somewhat higher, but many of the other recommendations should still apply.
Most of the children in our survey, who attended the paediatric clinic, were given nebulisers for use with sodium cromoglycate alone, as they were too young to use conventional treatnent. In some cases the paediatric clinic was unaware that bronchodilators were also being administered, and the mothers had presumably obtained their supplies of salbutamol from their general practitioners. Many other disquieting facts came to light, such as the unprescribed use of a nebuliser by a child at a play group and by a mother to treat her 9 month old baby. After these data were presented at a local medical meeting other patients with home nebulisers in the district were brought to our notice, so we cannot claim that this survey is a comprehensive review. Nevertheless, it has confirmed our suspicions that some patients are being prescribed nebulisers with limited or no instruction or supervision, which could lead to disaster.
Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis SAM A CHARHON, PASCALE M CHAVASSIEUX, PIERRE J MEUNIER, MICHELE ACCOMINOTTI Abstract Serum aluminium concentrations and biopsy specimens of bone were examined in 56 patients with end stage chronic renal failure receiving maintenance haemodialysis. Deposits of aluminium in bone specimens were often associated with low bone formation with or without osteomalacia. Serum aluminium concentrations of greater than 3-7 ,umol/l (10 sug/100 ml) indicated a high probability of deposits of aluminium in bone specimens, Introduction Long term consumption of phosphate binders containing aluminium or contamination of dialysis water with aluminium, or both, lead to the accumulation of aluminium in patients with chronic renal failure undergoing haemodialysis. Overload of aluminium has been shown to be responsible for vitamin D resistant osteomalacia, encephalopathy, and anaemia. Serum aluminium concentrations are often increased in these patients, but it is not known whether measurement of these concentrations is useful and sufficiently discriminative for the assessment of aluminium intoxication in patients receiving haemodialysis.
Gilli et al found that serum aluminium concentrations did not reflect the cumulative amount of aluminium ingested and did not help to predict the risk of accumulation of aluminium.' Cundy and Kanis considered that a serum aluminium concentration of greater than 7 ,umol/l (18-9 ,ug/100 ml) should alert the clinician to an appreciable risk of toxicity but that the best diagnostic indicator of aluminium toxicity in bone was the biopsy finding of aplastic osteomalacia (osteomalacia without increased osteoblastic and osteoclastic population).2 Verbeelen et al concluded that patients receiving dialysis are at risk of aluminium intoxication when their serum aluminium concentrations exceed 3-7 ,tmol/l (10 ,g/100 ml).3 In all these studies, however, the presence of aluminium in bone was not reported. Bone aluminium overload can be shown by a specific histochemical method (Aluminon staining) or the determination of the bone aluminium content by atomic absorption spectrophotometry, or both. The histochemical method can be used routinely whereas atomic absorption spectrophotometry requires special attention to avoid contamination of the biopsy specimens of bone.
We examined serum aluminium concentrations and biopsy specimens of bone in 56 patients with end stage chronic renal failure receiving maintenance haemodialysis.
Patients, methods, and results
We studied 56 patients (25 women and 31 men aged 18-77; mean (SD) age 43-3 (14 7)) with end stage chronic renal failure who had been receiving maintenance haemodialysis for 66 (38 2) months. All patients had received oral aluminium hydroxide since starting dialysis, but only 49 patients were receiving aluminium hydroxide (1-5-8-0 g daily) at the time of our study. As biopsies of bone were referred to our laboratory from different dialysis centres, it was not possible to determine the aluminium content of the dialysate used within the months preceding the study. Serum aluminium concentrations were measured by atomic absorption spectrophotometry (PerkinElmer 5000 spectrophotometer), and a biopsy specimen of the transiliac bone was taken from each patient after tetracycline double labelling. Histomorphometric analysis of undecalcified sections was performed according to methods published previously. 4 The presence of aluminium in bone was shown by a staining procedure using aurin tricarboxylic acid (Aluminon).
Bone lesions were classified as predominant hyperparathyroidism when the osteoclastic resorption surfaces were appreciably increased (greater than the mean value + 2 SD found in 130 normal controls) and the thickness of the osteoid seams was within the normal range indicating the absence of osteomalacia; as predominant osteomalacia when an appreciable increase in the thickness of the osteoid seams was associated with a reduced rate of calcification; and as low bone turnover when resorption surfaces and formation of bone were normal or decreased without evidence of osteomalacia.
Deposits of aluminium were seen in bone specimens from 39 patients, mainly localised at the mineralisation fronts and at the neutral surfaces. Seventeen patients had no stainable aluminium in their bone specimens. The mean serum aluminium concentration was significantly greater in patients who had deposits of aluminium in their bone (5-8 (4-7) ,umol/l (15-7 (12-7) jLg/10O ml)) than in those who had no stainable aluminium (1 9 (1 1) ,umol/l (5-1 (2 9) .g/100 ml)) (p < 0-001, Student's t test). All except one of the 23 patients whose serum aluminium concentration was greater than 3-7 ztmol/l (10 itg/ 100 ml) had stainable bone aluminium and hyperparathyroidism (seven patients), osteomalacia (12), or low bone turnover (three). Eleven out of 12 patients with serum aluminium concentrations greater than 7-4 utmol/l (20 u&g/100 ml) had either osteomalacia related to aluminium (nine patients) or low bone turnover (two). Over half of the patients (17/33) with serum aluminium concentrations lower than 3-7 jumol/l (10 ug/100 ml) had stainable bone aluminium, which was associated with osteomalacia in seven patients and with low bone turnover in another seven. The 16 patients who had no stainable aluminium with serum aluminium concentrations lower than 3-7 mmol/l (10 Hg/100 ml) showed hyperparathyroidism (n = 14) or low bone turnover (n = 2). Finally, among patients with deposits of aluminium in their bone there was no significant difference in mean serum aluminium concentration between those with hyperparathyroidism (5-8 (2 6) ,4mol/l (15-7 (7T0) ,g/100 ml); n = 10), osteomalacia (6-6 (5 8) umol/l (17-8 (15-7) pg/100 ml); n= 19), and low bone turnover (4-3 (3 9) phmol/l (11-6 (10-5) ug/100 ml); n= 10).
Comment
This study shows that serum aluminium concentrations of greater than 3-7 ,Lmol/l (10 ,ug/100 ml) indicate a high probability of deposits of aluminium in the bone as bone samples from 22 out of 23 patients with concentrations greater than this value contained stainable aluminium. High serum aluminium concentrations, however, did not predict the precise type of renal bone disease as they were associated with various bone lesions. Serum aluminium concentrations greater than 7-4 tmol/l (20 ,ug/100 ml), however, were often associated with osteomalacia. Nevertheless, the presence of bone disease related to aluminium in numerous patients whose serum aluminium concentrations were lower than [3] [4] [5] [6] [7] Cumol/l at biopsy confirms the limited predictive value of one measurement of serum aluminium concentration. The conditions of dialysis, especially the aluminium content of the dialysate used during the months preceding the study, were not known for all 17 patients who had deposits of aluminium in their bone, but the retrospective analysis of serum aluminium measurements performed within the year preceding the study was available for 11. Six of these 11 patients had at least one measurement of serum aluminium concentration greater than [3] [4] [5] [6] [7] ,tmol/l. The fairly low serum aluminium concentrations at the time of bone biopsy could reflect a reduction of exposure to aluminium before the time of the study. In contrast, among those patients with no stainable aluminium in their bone and with serum aluminium concentrations lower than [3] [4] [5] [6] [7] ,umol/l at the time of the study only two out of 14 had previously had a serum aluminium concentration slightly greater than 3-7 V±mol/l. Deposits of aluminium in bone could be associated with osteomelacia but also with low bone formation without osteomalacia, supporting a reduced synthetic activity of the osteoblasts at the cellular level. 5 Interestingly, increased bone formation has been reported in patients treated with desferrioxamine, a chelating agent for aluminium.
In conclusion, our study confirms that biopsy of bone is the best method of detecting aluminium intoxication of the bone. Serum aluminium concentrations are also helpful for diagnosing overload of aluminium in bone as concentrations above 3-7 ,umol/l are usually associated with stainable aluminium in the bone. A concentration of [3] [4] [5] [6] [7] ,umol/l under steady state conditions should be considered to be the threshold beyond which a biopsy of bone has to be performed to confirm the presence of deposits of aluminium and identify histological bone changes induced by aluminium. This could permit the early initiation of treatment with desferrioxamine to prevent the development of osteomalacia or encephalopathy, or both.
